Patient-derived organoids resemble the biology of tissues and tumors, enabling ex vivo
modeling of human diseases. They have heterogeneous morphologies with unclear biological …

Immunotherapy is the latest revolution in cancer therapy. It continues to show impressive
results in malignancies like melanoma and others. At least so far, effects are modest in …

Only a small subset of colorectal cancer (CRC) patients benefits from immunotherapies,
comprising blocking antibodies (Abs) against checkpoint receptor “programmed-cell-death-1” (…

Aberrant protease activity has been implicated in the etiology of various prevalent diseases
including neurodegeneration and cancer, in particular metastasis. Matrix-assisted laser …

Background 5-Fluorouracil (5-FU) is frequently used for the treatment of gastrointestinal
tumors. The pharmacological effect of 5-FU is influenced by genetic polymorphisms as well as …

Background In the group of elderly patients (≥70 years) with metastatic pancreatic ductal
adenocarcinoma (mPDAC), it is not known who benefits from intensive 1st line nab-paclitaxel/…

Background The overall survival of patients with advanced and refractory oesophageal
squamous cell carcinoma, mostly aged 65 years and older, is poor. Treatment with PD-1 …

Phosphoinositide (PIP) phosphatases such as myotubularins (MTMs) inhibit growth factor
receptor signaling. However, the function of myotubularin-related protein 7 (MTMR7) in cancer …

Docking protein-1 (DOK1) is a tumor suppressor frequently lost in malignant cells, however,
it retains the ability to control activities of immune receptors in adjacent stroma cells of the …

Background Advanced esophageal squamous cell cancer (ESCC) is frequently diagnosed
in elderly patients. The impact of 2nd line chemotherapy is poorly defined. Recent data …